Call for Abstract

21st International Conference on Breast Pathology and Cancer Diagnosis, will be organized around the theme “Exploring the Spectrum: Advances in Breast Pathology”

Breast Pathology 2024 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Breast Pathology 2024

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

This track focuses on the latest advancements in molecular pathology techniques and their application in unraveling the intricate subtypes of breast cancer. With the advent of genomic profiling and molecular markers, this session aims to explore the diverse molecular landscapes that underlie breast cancer, including hormone receptor-positive, HER2-positive, and triple-negative subtypes. Experts will discuss the molecular signatures, genomic alterations, and gene expression profiles associated with these subtypes, enabling a deeper understanding of their unique characteristics and implications for prognosis and treatment. Attendees will gain insights into the evolving field of molecular pathology, its impact on breast cancer classification, and the potential for personalized therapeutic interventions.

  • Track 1-1Epigenetic Modifications and Breast Cancer Subtypes
  • Track 1-2Emerging Technologies in Molecular Pathology: Advancements in Breast Cancer Subtyping
  • Track 1-3Genomic Profiling of Breast Cancer: Uncovering Molecular Alterations
  • Track 1-4Signaling Pathways and Molecular Subtypes of Breast Cancer
  • Track 1-5Transcriptomic Signatures in Breast Cancer: Gene Expression Profiling

This track focuses on the diagnostic challenges encountered in the spectrum of breast lesions, specifically from atypical ductal hyperplasia (ADH) to ductal carcinoma in situ (DCIS). With the increasing use of and detection techniques, the identification and accurate diagnosis of these lesions have become crucial for appropriate patient management. This track explores the complexities involved in distinguishing between ADH and DCIS, discussing the overlapping morphological features, immunohistochemical markers, and molecular characteristics that aid in differential diagnosis. The track also highlights the latest advancements in diagnostic tools, including genomic profiling and molecular testing, aiming to enhance diagnostic accuracy and guide optimal treatment strategies for patients with ADH and DCIS.

  • Track 2-1Histopathological Evaluation: Morphological Criteria and Interpretation Challenges
  • Track 2-2Radiological-Pathological Correlation: Enhancing Diagnostic Accuracy
  • Track 2-3Biomarkers and Molecular Profiling: Identifying High-Risk Lesions
  • Track 2-4Management Dilemmas: Overdiagnosis and Overtreatment
  • Track 2-5Emerging Techniques and Technologies: Improving Diagnostic Precision

Precision Medicine in Breast Pathology: Integrating Genomics and Targeted Therapies delves into the transformative potential of precision medicine approaches in breast cancer diagnosis and treatment. This track focuses on the integration of genomics, molecular profiling, and advanced technologies to identify specific genetic alterations and biomarkers that guide targeted therapies. Experts will present cutting-edge research on genomic profiling techniques, such as next-generation sequencing and gene expression profiling, and their implications in personalized treatment strategies. Discussions will revolve around the efficacy and limitations of targeted therapies, including hormone therapy, HER2-targeted therapy, and emerging immunotherapies. This track aims to highlight the latest breakthroughs in precision medicine, emphasizing its role in optimizing patient outcomes and shaping the future of breast cancer management.

  • Track 3-1Genomic Profiling and Biomarkers: Exploring Genomic Alterations in Breast Cancer
  • Track 3-2Targeted Therapies in Breast Cancer: Personalizing Treatment Approaches
  • Track 3-3Liquid Biopsies and Circulating Tumor DNA (ctDNA): Non-invasive Genomic Testing
  • Track 3-4Overcoming Resistance to Targeted Therapies: Mechanisms and Strategies
  • Track 3-5Clinical Implementation of Precision Medicine: Challenges and Opportunities

The track on "Immunohistochemistry and Biomarkers in Breast Pathology" focuses on the critical role of immunohistochemistry (IHC) and biomarkers in the diagnosis, prognosis, and treatment of breast pathology. This track explores the latest advancements in IHC techniques, including the identification and evaluation of key biomarkers such as hormone receptors (ER, PR), HER2/neu, Ki-67, and other emerging markers. Discussions will revolve around their clinical significance, interpretation challenges, and their impact on therapeutic decision-making. Additionally, this track will delve into novel biomarkers and their potential for risk assessment, predicting treatment response, and guiding personalized treatment strategies. Attendees will gain insights into the evolving landscape of IHC and biomarkers, enhancing their understanding of breast pathology evaluation and patient management.

  • Track 4-1Biomarkers for Breast Cancer Subtyping
  • Track 4-2Emerging Biomarkers in Breast Pathology
  • Track 4-3Immunohistochemistry Techniques and Interpretation
  • Track 4-4Role of Immunohistochemistry in Differential Diagnosis
  • Track 4-5Predictive and Prognostic Biomarkers

The track "Breast Imaging: Innovations in Radiology and Pathology Correlation" focuses on the latest advancements in imaging techniques for breast pathology and the correlation between radiological findings and pathological assessment. This track will delve into cutting-edge innovations in breast imaging, such as digital mammography, tomosynthesis, magnetic resonance imaging (MRI), and molecular imaging modalities. Discussions will revolve around the integration of imaging findings with pathological analysis to enhance diagnostic accuracy, improve treatment planning, and optimize patient outcomes. Attendees will gain insights into the evolving field of breast imaging, explore the challenges and opportunities in radiology-pathology correlation, and understand the implications for clinical decision-making in breast pathology.

  • Track 5-1Breast Imaging: Innovations in Radiology and Pathology Correlation
  • Track 5-2Radiogenomics: Integrating Radiological and Genomic Features for Improved Diagnosis
  • Track 5-3Artificial Intelligence and Machine Learning in Breast Imaging

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

  • Track 6-1Molecular Subtypes and Biomarkers in Triple-Negative Breast Cancer
  • Track 6-2Therapeutic Strategies and Future Directions for Triple-Negative Breast Cancer

"Emerging Technologies in Breast Pathology: Digital Pathology, AI, and Machine Learning" explores the transformative potential of cutting-edge technologies in breast pathology. This track focuses on digital pathology, which enables the digitization of histopathology slides for improved storage, accessibility, and collaboration. It delves into the utilization of artificial intelligence (AI) and machine learning algorithms for tasks such as image analysis, lesion detection, and prognostic prediction in breast pathology. Attendees will gain insights into the latest advancements, challenges, and opportunities associated with these technologies, their integration into routine practice, and their potential to enhance accuracy, efficiency, and personalized patient care in the field of breast pathology.

  • Track 7-1Digital Pathology: Advancements and Applications
  • Track 7-2Artificial Intelligence and Machine Learning in Breast Pathology

Benign Breast Lesions: Diagnosis, Management, and Surveillance focuses on the diagnosis, management, and surveillance of benign breast lesions. Benign breast lesions are common findings in clinical practice, and accurate diagnosis is crucial to distinguish them from malignant counterparts. This track delves into the latest advancements in diagnostic techniques, including imaging modalities, biopsy approaches, and pathological assessment. It also explores the management strategies for benign breast lesions, ranging from conservative observation to surgical interventions, and discusses the long-term surveillance and follow-up considerations. Attendees will gain insights into the optimal management strategies, risk assessment tools, and the evolving landscape of benign breast lesion diagnosis, ensuring improved patient care and outcomes.

  • Track 8-1Diagnostic Challenges and Imaging Modalities for Benign Breast Lesions
  • Track 8-2Management Strategies and Surveillance Protocols for Benign Breast Lesions

Breast Pathology in Pregnancy and Lactation: Challenges and Considerations focuses on the unique challenges and considerations involved in diagnosing and managing breast pathology during pregnancy and lactation. Pregnancy and lactation introduce hormonal changes and physiological adaptations in the breast, making the evaluation and interpretation of breast lesions more complex. This track aims to explore the impact of pregnancy and lactation on breast pathology, including the diagnosis of benign and malignant breast lesions, the safety of imaging modalities and biopsy techniques, hormonal influences on tumor behavior, and the implications for treatment decisions. The discussions will provide valuable insights to pathologists, radiologists, obstetricians, and oncologists involved in the care of pregnant and lactating patients with breast pathology.

  • Track 9-1Hormonal Changes and Breast Pathology during Pregnancy and Lactation
  • Track 9-2Diagnostic Dilemmas and Management Strategies for Breast Lesions in Pregnancy and Lactation

"Metastatic Breast Cancer: Pathological Insights and Treatment Approaches," focuses on the critical aspects of metastatic breast cancer from a pathological perspective. It aims to provide a deeper understanding of the underlying mechanisms of metastasis, the molecular characteristics associated with metastatic breast cancer, and the challenges in diagnosing and classifying metastatic lesions. Additionally, this track explores the latest advancements in treatment approaches for metastatic breast cancer, including targeted therapies, immunotherapies, and emerging treatment modalities. Through insightful presentations and discussions, attendees will gain valuable insights into the pathological features of metastatic breast cancer and the evolving landscape of treatment options for improved patient outcomes.

  • Track 10-1Molecular Profiling and Biomarkers in Metastatic Breast Cancer
  • Track 10-2Novel Therapeutic Strategies for Metastatic Breast Cancer

This track focuses on the crucial topic of "Pathological Assessment of Breast Core Biopsies: Pitfalls and Best Practices." It aims to address the challenges encountered during the evaluation of breast core biopsies and explore the optimal strategies for accurate diagnosis. The track will delve into common pitfalls, such as sampling errors, inadequate tissue acquisition, and interpretation challenges. It will highlight the importance of incorporating ancillary studies, including immunohistochemistry and molecular testing, to enhance diagnostic accuracy. Experts in breast pathology will share their experiences; discuss quality assurance measures, and present best practices for evaluating breast core biopsies, ultimately improving patient care and treatment decision-making.

  • Track 11-1Pitfalls in Pathological Assessment of Breast Core Biopsies: Challenges and Solutions
  • Track 11-2Best Practices in Pathological Assessment of Breast Core Biopsies: Improving Accuracy and Consistency

This track will delve into the pathogenesis, diagnosis, and therapeutic advances in inflammatory breast cancer (IBC). Participants will gain insights into the unique characteristics of IBC, including its aggressive nature and distinctive clinical presentation. The discussions will focus on unraveling the underlying molecular mechanisms contributing to IBC development and progression. Diagnostic challenges, such as differentiating IBC from other breast malignancies, will be addressed, emphasizing the importance of accurate and timely diagnosis. Furthermore, cutting-edge therapeutic strategies and emerging treatment modalities specific to IBC will be explored, highlighting the latest advancements and clinical trials that aim to improve outcomes for patients with this challenging form of breast cancer.

  • Track 12-1Pathogenic Mechanisms and Molecular Signatures
  • Track 12-2Diagnostic Challenges and Advances

The track on "Pathological Assessment of Breast Reconstruction: Challenges and Surgical Considerations" focuses on the complexities and unique aspects of assessing breast tissue following reconstructive procedures. This track explores the challenges faced by pathologists when evaluating post-reconstruction specimens, including distinguishing normal tissue from residual or recurrent cancer, identifying implant-associated changes, and interpreting the effects of radiation therapy. Additionally, it delves into the histopathological evaluation of various types of breast reconstructions, such as autologous flaps and implant-based reconstructions, addressing the impact of surgical techniques on pathological assessment. This track aims to enhance understanding, promote best practices, and foster collaboration between pathologists and reconstructive surgeons in optimizing the assessment of reconstructed breast tissue.

  • Track 13-1Evaluation of Surgical Techniques in Breast Reconstruction: Assessing Efficacy and Complications
  • Track 13-2Pathological Assessment of Breast Implants and Tissue Expanders: Diagnostic Challenges and Management Strategies

Biomarkers and Predictive Factors in Breast Pathology: Translating Research into Clinical Practice focuses on the critical role of biomarkers and predictive factors in breast pathology, aiming to bridge the gap between research discoveries and their practical application in clinical practice. The sessions within this track will explore the latest advancements in identifying and understanding biomarkers that aid in the diagnosis, prognosis, and treatment selection for breast cancer patients. From genomic and proteomic markers to hormone receptors and HER2/neu status, experts will discuss the clinical implications, validation studies, and guidelines for incorporating these biomarkers into routine practice. Attendees will gain valuable insights into how biomarkers and predictive factors are transforming breast pathology and enhancing personalized patient care.

  • Track 14-1Biomarkers for Predicting Response to Therapy
  • Track 14-2Prognostic Biomarkers in Breast Pathology

"Multidisciplinary Approach to Breast Pathology: Collaboration between Pathologists, Radiologists, Surgeons, and Oncologists" emphasizes the significance of teamwork and cooperation among healthcare professionals involved in the diagnosis, treatment, and management of breast pathology. This track highlights the importance of integrating the expertise of pathologists, radiologists, surgeons, and oncologists to ensure comprehensive patient care. Discussions within this track will focus on effective communication, interdisciplinary tumor board meetings, shared decision-making, and the latest advancements in collaborative practices. By fostering a multidisciplinary approach, this track aims to enhance diagnostic accuracy, optimize treatment planning, and improve patient outcomes in the field of breast pathology.

  • Track 15-1Tumor Board Meetings: Enhancing Collaboration and Treatment Planning
  • Track 15-2Imaging-Pathology Correlation: Bridging the Gap for Accurate Diagnoses